

THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Michaelides M, Laich Y, Wong SC, et al. Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study. *Lancet* 2025; **405**: 648–57.

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Appendix

Table of Contents

Supplementary Methods 1

 Surgical administration of AAV8.hRKp.AIP1 1

 Measurement of visual acuity by Cardiff Cards 1

 Measurement of visual acuity by Kays Pictures 2

 Measurement of visual acuity by Sonksen LogMAR test 2

 Measurement of visual acuity by PopCSF 3

 Measurement of cortical responses to visual stimuli by steady-state visually evoked potentials 3

 Retinal imaging 5

Supplementary Results 6

 Supplementary Figure 1 Wide-field color fundus imaging and fundus autofluorescence (FAF) captured by Optos Panoramic 200 following treatment 6

 Supplemental Figure 2 Cortical responses to all visual stimulus conditions (full-field and grating stimuli) measured by visually evoked potentials 7

 Videos 9

References 12

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

21 **Supplementary Methods**

22

23 **Surgical administration of AAV8.hRKp.AIP1**

24

25 Three-port 23-gauge pars plana vitrectomy was performed by a single surgeon (CW).

26 Vitrectomy surgery included induction of posterior hyaloid separation from the

27 posterior pole using the vitrectomy cutter. AAV2/8.hRKp.AIP1 vector suspension was

28 administered at a titer of 1×10^{11} vg/mL into the subretinal space, using a 41-gauge subretinal

29 cannula via a single retinotomy positioned adjacent to the superotemporal vascular arcade.

30 The aim was to generate a bleb involving the posterior pole and extending from the superior

31 retinal vascular arcade to the inferior arcade. Intraoperative OCT was used to confirm the

32 anatomical location of the bleb. The vitreous cavity was washed out using infusion fluid for 2

33 minutes to remove vector that may have refluxed from the bleb. The sclerotomies were

34 closed using 8/0 polyglactin sutures (Vicryl; Ethicon Inc). Dexamethasone and cefuroxime

35 were administered subconjunctivally. Postoperatively, eye drops containing a combination of

36 1 mg dexamethasone, 6000 IU polymyxin B sulphate and 3500 IU neomycin sulphate

37 (Maxitrol, Novartis UK) were prescribed to be used four times daily for four weeks. To

38 protect against intraocular inflammation, children were prescribed oral prednisone, at a dose

39 of 1.0 mg/Kg bodyweight daily for 5 days before surgery, 1 mg/Kg for the first week after

40 surgery, 0.8 mg/Kg for the second week, 0.6 mg/Kg for the third week, 0.4 mg/Kg for the

41 fourth week and 0.2 mg/Kg for the fifth week. Ranitidine 2.0 mg/Kg bodyweight or

42 omeprazole 10 mg once daily were prescribed for the duration of the steroid regimen to

43 protect against harm from gastric adverse effects.

44

45 **Measurement of visual acuity by Cardiff Cards**

46

47 There are 13 visual acuity levels in a full set of Cardiff Cards with 3 cards at each level.

48 Before starting the examiner ensures that the cards are in order and all facing downwards.

49 The position of the optotype, top or bottom, should be unknown to the examiner to avoid

50 examiner bias. The cards are presented vertically at either 50cm or 1m depending on the

51 patient's cooperation and visual potential. Starting at 1m, the distance is reduced if unable to

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

52 get a response at the largest size. 3 cards are presented at each acuity, to confirm acuity
53 achieved. If the examiner is struggling to confirm a seeing response the card can be rotated to
54 a horizontal position. If the child does not see 2 out of 3 cards on an acuity level, the previous
55 acuity level is repeated to confirm that this is their level of VA.

56

57 Measurement of visual acuity by Kays Pictures

58

59 The child is asked to name all pictures on the matching card. If limited confidence or delayed
60 speech, the child is allowed to match the optotypes. One eye is occluded with glasses if no
61 prescription glasses worn. At 3 metres distance the book is opened a large size picture is
62 presented to the child. The child is asked to name the first (or last) picture in the row, and
63 indicate that picture by briefly pointing to it. This is repeated with smaller sizes until a size is
64 reached where they cannot see either the first or the last picture in the row. Then the other
65 pictures in that row are presented. If two or more pictures in that row can be seen, testing is
66 continued at the next size smaller. If none or only one picture can be seen, the next size larger
67 is used, checking all four pictures. The second eye is similarly tested by occluding the first
68 eye.

69

70 Measurement of visual acuity by Sonksen LogMAR test

71

72 The child is familiarised with all the letters within the test; O, X, H, Y, U and V. Sheridan
73 Gardiner letters can be used. If unable to name all the letters, a matching card is used. One
74 eye is occluded with prescription glasses or occlusion glasses if prescription glasses are not
75 worn. The child is presented with a flipbook, 4 letters within a box. Standing 3m away the
76 child is presented with the largest letter to identify. The child is asked to identify each of the
77 letters in the booklet of starting with the 0.7 letter until a letter is not seen correctly. If a child
78 is unable to see some of the letters at the starting level, the tester presents the preceding larger
79 displays until a full line is identified; the child is then shown each letter in turn until three
80 consecutive letters are failed. Every letter correctly identified after the last whole line
81 achieved contributes to the score. The test is continued until 3 out of the 4 letters are
82 incorrectly named and record. The test is repeated with the second eye.

83

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

84 Measurement of visual acuity by PopCSF

85

86 In addition to conventional testing of visual acuity by identification of letters and shapes, we
87 also measured visual acuity objectively using a novel gamified touchscreen-based test named
88 the PopCSF test¹ designed to address the challenges of measuring visual function in young
89 children with severe sight impairment. In this test, children are presented with localised
90 drifting grating patterns ('bubbles') and asked to touch ('pop') them on the screen. An
91 adaptive algorithm² adjusts the spatial frequency and contrast of these gratings, based on the
92 participant's performance. To maintain constant spatial frequencies across viewing distance,
93 real-time head-tracking with the tablet's front-facing camera is used to adjust physical spatial
94 frequencies. The likelihood of randomly touching a grating on the screen is very low, with a
95 ~1% chance of any touched pixel falling inside a grating. Conservatively, we define chance-
96 level performance as success rates of 10% or below. We used logistic regression to compare
97 the relationship between hit rate and target spatial frequency across the two eyes.

98 Additionally, to assess grating acuity limits, we categorized the targets into three categories
99 based on their spatial frequency: low (1.5-2.5 cycles per degree (cpd)), medium (2.5-3.5
100 cpd), and high (>3.5 cpd), and compared the hit rates in each category to a 10% chance level
101 using exact binomial tests. Since these measures are based on drifting gratings, they are not
102 directly comparable to standard acuity tests. However, converted to LogMAR acuity they
103 correspond approximately to 1.10-1.30, 0.95-1.10, and < 0.95 logMAR. For Child 2 we
104 excluded three invalid grating targets from the analysis because they had been viewed
105 binocularly.

106

107 Measurement of cortical responses to visual stimuli by steady-state visually evoked
108 potentials

109

110 We measured visual signal detection in the visual cortex using the steady-state visually
111 evoked potential (ssVEP) technique³⁻⁵ by recording cortical electrophysiological responses to
112 full-screen black/white flickering stimuli and flickering (contrast-reversing) gratings across a
113 range of spatial frequencies. Main analyses focus on the full-screen stimuli, data for gratings
114 are in Supplemental Figure 2. Testing was conducted with a wide screen setup (65° width, 55

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

115 cm viewing distance, 380 cd/m² peak luminance) using a Biosemi system.⁶ Ambient light
116 levels were mesopic and constant across sessions and patients. Children were not dark-
117 adapted. Individually sized head caps were used to ensure stable and consistent electrode
118 sensor positioning over occipital cortex. Full-field flicker and spatial frequency conditions
119 were administered in 2-second intervals and repeated 9-12 times for each eye. Because a
120 secondary objective of this study was to determine the optimal testing parameters for
121 measuring treatment-related change in ssVEPs in this cohort for future studies, spatial and
122 temporal frequencies of the gratings were varied across participants. Child 1 underwent
123 testing with full-screen black-white flicker and sinusoidal gratings of 0.5, 1, and 3 cpd, each
124 contrast-reversing at a 7.5 reversals per second (rps). Child 2 was tested with a full-screen
125 black-white flicker and checkerboard gratings of 0.3, 1, and 3 cpd, each flickering at 15 rps.
126 Despite these variations in stimulus parameters between individuals, within-subject
127 comparison of treated versus untreated eyes is valid. Retinocortical acuity, reflected in
128 ssVEPs, was assessed by first referencing the electrical signal from a central occipital
129 electrode (Oz in the 10-20 system) over the occipital pole to the average of two adjacent
130 electrodes (O1 and O2). This signal was then averaged across repetitions for each condition
131 and transformed into the frequency domain via a discrete Fourier transform. No offline noise
132 filtering or epoch rejection was applied to the raw EEG signal. Fourier analysis was used to
133 distinguish the recovering visual signal at the stimulus flicker frequency from noise. For a
134 grating that can be detected, visual cortex activity is expected to synchronise with the
135 stimulus flicker frequency, thus increasing signal power at this temporal frequency.
136 Conversely, a grating beyond the acuity limit that this method can detect is not expected to
137 increase power at the stimulus flicker frequency. A significant therapy effect is measured as
138 the relative increase in power between the treated versus untreated eye. To verify that signal
139 enhancement is specific to the visual stimulus frequency, signal-to-noise ratio (SNR) was
140 computed by dividing the power at the target frequency by the average power of the two
141 neighbouring frequency bins of non-interest.^{7,8} To determine the statistical significance of
142 ocular differences in ssVEP signal we adopted a permutation-based strategy.⁹ This approach
143 involved randomly resampling the repetitions within each condition and repeating the
144 analysis steps as described above 10,000 times to generate a surrogate null distribution of

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

145 differences between eyes. We determined the statistical significance by comparing the actual
146 observed difference against this generated null distribution.

147

148 Retinal imaging

149

150 Retinal imaging was performed using handheld spectral-domain optical coherence
151 tomography (OCT; Figure 4) (Envisu C2300; Leica Microsystems, United Kingdom) and
152 wide-field fundus autofluorescence imaging (Supplementary Figure 1; Optos Panoramic 200;
153 Optos PLC, United Kingdom). Rectangular, horizontal OCT volume scans were obtained
154 using the Free Run mode with an 8mm nominal width, 1000 A-scans per B-scan, 75 B-scans
155 and 1 frame per B-scan.


THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

156 **Supplementary Results**

157

158 Supplementary Figure 1 Wide-field color fundus imaging and fundus

159 autofluorescence (FAF) captured by Optos Panoramic 200 following treatment



160

161 Panel A; Child 1, 6 years old, 3.4 years after treatment; Panel B; Child 2, 5.1 years old, 2.3

162 years after treatment; Panel C; Child 3, 3.2 years old, 2.3 years after treatment; image


163 acquisition of the untreated eye was not possible owing to limited cooperation; Panel D;

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

164 Child 4, 4.2 years old, 2.1 years after treatment; FAF acquisition of the untreated eye was not
 165 possible owing to limited cooperation. Asterisks denote the treated eye.

166

167 Supplemental Figure 2 Cortical responses to all visual stimulus conditions (full-field
 168 and grating stimuli) measured by visually evoked potentials



169

170

171 Panels A (Child 1) and B (Child 2) show occipital steady-state visually evoked potentials
 172 (ssVEP) obtained from EEG, for each child's treated eye (red circles and lines) and untreated
 173 eye (blue grey circles and lines). Children viewed flickering contrast reversing stimuli at
 174 55cm on a 65° wide screen, including full-screen flicker (0.0 cycles per degree, cpd) and
 175 gratings with a range of spatial frequencies up to 3cpd (Figure 1). Data were recorded in 2s
 176 segments and averaged across multiple repeats per condition with no off-line data filtering or
 177 epoch rejection (n=9-12). A discrete Fourier transform was used to compute signal power at
 178 and around the flicker frequency. Whiskers represent bootstrapped standard errors. Both
 179 children showed clear responses at the stimulus flicker frequency for their treated eye (red
 180 lines). As reported in Main Figure 3A, permutation tests revealed that both children's treated
 181 eyes showed a significantly enhanced response to full-screen flicker compared to the

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

182 untreated eye. For spatial frequency stimuli, no significant ssVEP amplitude differences were
183 detected before or after treatment, highlighting the full-screen condition as the more robust
184 test of treatment effects. Stars indicate statistically significant differences ($p < 0.05$) between
185 the two eyes. Panels C (Child 1) and D (Child 2) show the power spectra at the stimulus
186 flicker frequency (set to zero for visualization, darkly coloured bars) and at neighbouring
187 temporal frequencies of non-interest (lightly coloured bars) for their treated eye (red) and
188 untreated eye (blue).

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

189 **Videos**

190

191 Video 1

192 Child 1, 4·1 years after treatment: assessment of functional vision

193 Child 1 is asked to locate white objects of various sizes against a black background using
194 each eye in turn, with the other eye occluded. Using the sight of her treated right eye (OD)

195 alone she accurately locates white object of 5 mm, 3 mm, and 1 mm diameter. Using her
196 untreated left eye (OS) alone she is unable to locate even the largest (5 mm) object. Instead,
197 she adjusts the spectacles to unmask her treated right eye.

198

199 Video 2

200 Child 1, approximately 1 year after treatment: vision-guided behaviour

201 This video was provided by family of Child 1 while she was unable to travel to the UK for
202 formal assessment during the COVID19-pandemic. With both eyes open, she accurately and
203 repeatedly locates a bottle on the floor using her sight.

204

205 Video 3

206 Child 1, 4·1 years after treatment: assessment of functional vision

207 Child1 is asked to transfer crayons from one cup to another using her treated right eye (OD)
208 alone. She appears to use her sight to locate the missed crayons.

209

210 Video 4

211 Child 1, 4·1 years after treatment: assessment of vision-guided mobility

212 Child 1 is asked to walk the length of the corridor with the use of both her treated and
213 untreated eyes. She completes the task safely and confidently using her sight alone. When
214 asked to locate the second door she completes the task safely and accurately using her sight
215 alone.

216

217 Video 5

218 Child 2, 3.4 years after treatment: assessment of functional vision

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

219 Child 2 is asked to locate white objects of various sizes against a black background using
220 each eye in turn, with the other eye occluded. Using the sight of her treated left eye (OS)
221 alone she accurately locates objects of 5 mm, 3 mm, and 1 mm diameter. Using her untreated
222 right eye (OD) alone she is unable to locate even the largest (5 mm) object; instead, she
223 adjusts the spectacles to unmask the sight of her treated left eye (OS).

224

225 Video 6

226 Child 2, 2.3 years after treatment: vision-guided behaviour

227 Child 2, with the use of both her treated and untreated eyes, uses her sight to draw using
228 coloured pens.

229

230 Video 7

231 Child 2, 3.4 years after treatment; assessment of functional vision

232 Child 2 is asked to transfer crayons from one cup to another using each eye in turn with the
233 other eye occluded. Using her treated left eye (OS) alone she completes the task confidently,
234 appearing to locate the missed crayons using her sight. In contrast, using the sight of her
235 untreated right eye (OD) alone she appears to rely heavily on tactile cues and her memory of
236 the cup's location. When the cup's location is changed, she fails to identify its new position.
237 Instead, she adjusts the spectacles to unmask the sight of her treated left eye (OS).

238

239 Video 8

240 Child 2, 3.4 years after treatment: writing skills

241 Child 2, with the use of both her treated and untreated eyes, uses her sight to write letters and
242 draw shapes.

243

244 Video 9

245 Child 2, 3.4 years after treatment: vision-guided mobility

246 Child 2, with the use of both her treated and untreated eyes, navigates confidently and safely
247 using her sight alone. She runs along a corridor, sits at a table, locates the examination room
248 and steps up to sit in the examination chair.

249

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

250 Video 10

251 Child 3, 2·3 years after treatment: assessment of functional vision

252 Child 3, with the use of both his treated and untreated eyes, plays with toys and transfers
253 crayons from one cup to another. He appears to use his sight to locate missed crayons.

254

255 Video 11

256 Child 3, 3·5 years after treatment: assessment of functional vision

257 Child 3, with the use of both his treated and untreated eyes, removes and replaces a 1 cm
258 diameter white object from a transparent tube. He appears to use his sight to complete the
259 task.

260

261 Video 12

262 Child 3, 3·5 years after treatment: assessment of vision-guided mobility

263 Child 3, with the use of both his treated and untreated eyes, runs confidently and safely along
264 a corridor.

265

266 Video 13

267 Child 4, 2·9 years after treatment: assessment of functional vision

268 Child 4, with the use of both his treated and untreated eyes, accurately
269 locates a white object of 5mm diameter against a black background. Neither monocular
270 assessment nor location of smaller objects were possible owing to limited compliance.

271

272 Video 14

273 Child 4, 2·9 years after treatment: assessment of vision-guided navigation

274 Child 4, with the use of both his treated and untreated eyes, walks comfortably along a
275 corridor. He makes unintended contact with a fire extinguisher but otherwise completes the
276 task without error.

277

278

THELANCET-D-24-05940 Gene therapy in children with *AIP1*-associated severe retinal dystrophy: an open-label, first-in-human interventional study

279 **References**

280

281 1. Elfadaly D, Abdelrazik ST, Thomas PBM, Dekker TM, Dahlmann-Noor A, Jones PR.
282 Can Psychophysics Be Fun? Exploring the Feasibility of a Gamified Contrast Sensitivity
283 Function Measure in Amblyopic Children Aged 4–9 Years. *Frontiers in Medicine*. 2020;7.

284 Accessed December 17, 2023. <https://www.frontiersin.org/articles/10.3389/fmed.2020.00469>

285 2. Farahbakhsh M, Dekker TM, Jones PR. Psychophysics with children: Evaluating the
286 use of maximum likelihood estimators in children aged 4–15 years (QUEST+). *Journal of*
287 *Vision*. 2019;19(6):22. doi:10.1167/19.6.22

288 3. Hamilton R, Bach M, Heinrich SP, et al. VEP estimation of visual acuity: a systematic
289 review. *Doc Ophthalmol*. 2021;142(1):25-74. doi:10.1007/s10633-020-09770-3

290 4. Hoffmann MB, Brands J, Behrens-Baumann W, Bach M. VEP-based acuity
291 assessment in low vision. *Doc Ophthalmol*. 2017;135(3):209-218. doi:10.1007/s10633-017-
292 9613-y

293 5. Harris L, Atkinson J, Braddick O. Visual contrast sensitivity of a 6-month-old infant
294 measured by the evoked potential. *Nature*. 1976;264(5586):570-571. doi:10.1038/264570a0

295 6. Biosemi EEG ECG EMG BSPM NEURO amplifier electrodes.
296 <https://www.biosemi.com/>.

297 7. Meigen T, Bach M. On the statistical significance of electrophysiological steady-state
298 responses. *Doc Ophthalmol*. 1999;98(3):207-232. doi:10.1023/A:1002097208337

299 8. Norcia AM, Appelbaum LG, Ales JM, Cottareau BR, Rossion B. The steady-state
300 visual evoked potential in vision research: A review. *Journal of Vision*. 2015;15(6):4.
301 doi:10.1167/15.6.4

302 9. Westfall PH, Troendle JF. Multiple Testing with Minimal Assumptions. *Biom J*.
303 2008;50(5):745-755. doi:10.1002/bimj.200710456

304